Informação sobre produto
- Bryostatin1, 35-demethoxy-22,35-epoxy-, (22S)-
- 5,27:9,13:15,19-Triepoxy-2H-furo[2,3-e]oxacyclohexacosin,bryostatin 1 deriv.
- 2,4-Octadienoic acid,17-(acetyloxy)-4,5,6,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,25,26,27,27a-docosahydro-5,15,21-trihydroxy-25-(1-hydroxyethyl)-11-(2-methoxy-2-oxoethylidene)-6,6,16,16-tetramethyl-2,23-dioxo-5,27:9,13:15,19-triepoxy-2H-furo[2,3-e]oxacyclohexacosin-4-ylester,[4S-[4R*(2E,4E),5R*,7E,9S*,11Z,13R*,15R*,17R*,19S*,21S*,25S*(S*),27S*,27aR*]]-
Bryostatin 3 is a polyunsaturated fatty acid that has been shown to be a potent anticancer agent. It inhibits the growth of cancer cells by activating protein kinase C and phospholipase C, which are enzymes that regulate membrane function. Bryostatin 3 also exhibits antimicrobial activity against Gram-positive bacteria and HIV. The molecule is synthesized by the asymmetric addition of a hydroxyl group to an organic quinoline derivative. The effective dose for bryostatin 3 is 10-30 ng/kg body weight per day, and it can be given intravenously or orally.
Propriedades químicas
Consulta técnica sobre: 3D-TFA37084 Bryostatin 3
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.